IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
about
Diabetes Treatment — Bridging the DivideUnderstanding Idiopathic Interstitial Pneumonia: A Gene-Based Review of Stressed LungsEnergy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonistAccelerated recovery from acute hypoxia in obese mice is due to obesity-associated up-regulation of interleukin-1 receptor antagonist.Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK ratTime-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance.Circulating levels of interleukin-1 family cytokines in overweight adolescents.Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2.The association of insertions/deletions (INDELs) and variable number tandem repeats (VNTRs) with obesity and its related traits and complicationsAccelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study.In vivo immune signatures of healthy human pregnancy: Inherently inflammatory or anti-inflammatory?Early investigational drugs for hearing loss.Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus.Effects of resistance training on the inflammatory response.Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study.A novel bifunctional protein TNFR2-Fc-IL-1ra (TFI): expression, purification and its neutralization activity of inflammatory factors.In vivo evaluation of safety and toxicity of a Lactobacillus jensenii producing modified cyanovirin-N in a rhesus macaque vaginal challenge modelGenetic determinants of circulating interleukin-1 receptor antagonist levels and their association with glycemic traits.Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting.IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines.Expression and contributions of TRPM7 and KCa2.3/SK3 channels to the increased migration and invasion of microglia in anti-inflammatory activation statesThe roles of IL-6, IL-10, and IL-1RA in obesity and insulin resistance in African-AmericansIdentifying a major locus that regulates spontaneous arthritis in IL-1ra-deficient mice and analysis of potential candidatesAssociation between circulating ascorbic acid, α-tocopherol, 25-hydroxyvitamin D, and plasma cytokine concentrations in young adults: a cross-sectional study.Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instabilityExpression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD.Insulin signalling mechanisms for triacylglycerol storage.High glucose induces IL-1beta expression in human monocytes: mechanistic insights.Receptors for tumor necrosis factor-alpha play a protective role against obesity and alter adipose tissue macrophage statusInterleukin-1 Receptor Antagonist and Interleukin-4 Genes Variable Number Tandem Repeats Are Associated with Adiposity in Malaysian Subjects.Effects of exercise on inflammation markers in type 2 diabetic subjects.Targeting IL-1 in depression.Lack of Proinflammatory Cytokine Interleukin-6 or Tumor Necrosis Factor Receptor-1 Results in a Failure of the Innate Immune Response after Bacterial Meningitis.Tumorigenicity of IL-1alpha- and IL-1beta-deficient fibrosarcoma cells.A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.Antigenic and immunosuppressive properties of a trimeric recombinant transmembrane envelope protein gp41 of HIV-1Anti-inflammatory response following uptake of apoptotic bodies by meningothelial cells.Decreased circulating and neutrophil mediated VEGF-A165 release in stable long-term cardiac transplant recipientsHDAC3 inhibition ameliorates spinal cord injury by immunomodulation.Difference in inflammatory cytokine production by mononuclear cells from obese and non-obese schizophrenic patients.
P2860
Q22250871-EAEBC80E-C426-4D7B-BBCF-EB9985F1444DQ26779192-AE4095B0-1B7E-422D-A07C-8805F4A7A16EQ28569816-297161BD-0E9A-4068-BC45-609BDB37CCC2Q30487953-27EF635D-AEC5-4B66-982F-80B573185BBCQ33501717-3959E9B5-B7FF-41FF-B97E-A803E7D53D5DQ33526310-1ECDB253-4FEE-44C5-96A7-3DE42E7A4246Q33652307-B5B7ABD0-B7FE-451F-B4E5-9EB9D17D94B5Q33771582-3498E292-61EF-4E21-9E41-F27538258F4BQ33801241-8EFED9A5-90F1-4121-9886-FCD567DD2021Q33803480-EAC3B578-6EB5-4DB6-892C-6331370AC239Q33821861-02451968-EA83-45E3-A3D0-5D2C23485417Q33847686-0616E336-565D-4826-948E-F5BDAA8DA7AFQ34023565-55F6BE1B-741A-4C25-BD57-EB0CC0F57304Q34104494-335F241C-56C9-4C96-8F31-CAA28D388C63Q34252237-F84B13F9-38D6-4C32-B9B0-1B785C6BD595Q34261113-BF41DEEB-F454-4E7A-8A04-8B8E5891E884Q34387113-9D930643-E0EF-469D-B31C-7517B488EC14Q34545454-69D20B9F-89A9-4A56-855C-F6993401CAC7Q34731357-82728D2E-E075-44CB-A79A-E327B8FC6275Q34911427-F53039F2-D4B9-4C8B-97AA-A6275C5F326CQ35229982-4B757815-6F22-41B7-B1ED-5B5979D169D2Q35597876-E20272CE-8B47-4AFA-87F8-12D05D3FA203Q35633476-ED133CB7-DD36-46D8-A3EB-4833B4F95D32Q36448338-F504CF3B-5864-4480-ACE4-1CA10BF11F18Q36741853-C9A12191-919A-458C-AEC0-4A6A0BC7385BQ36764856-B4640160-BD8A-4484-A9CD-D75B894A7829Q36838847-B00EA421-3F16-4188-8A28-6DCC24EB68C6Q37176774-73E32546-8C18-49EA-B81B-F0E74B144BBEQ37328822-A4878619-1F3A-4A78-91AB-DE424C76A458Q37672823-A87AB777-D29D-4E8B-B43D-8C6E130FF8B5Q37856870-D306E111-D6AD-405D-91B6-332172994CCBQ38038284-10D18366-A9A2-44FD-B80B-8CFCC64850A0Q38363327-73C8E0B2-5502-40EC-8DDF-CE21E973777CQ38526464-C6EC7BED-79DD-4F12-9229-B5A924BB202CQ38730996-2AE7D3AC-AAC6-4F8E-AFFA-DEFE6013A302Q38914831-138DEEF3-FCE7-42CA-8A97-04674ABA61C9Q39021326-BAD6B8B4-B564-4279-AFDB-0BB0C27A9BF5Q39999470-C6DA901F-15B8-4601-8261-FDE59235EB75Q41447137-73143370-E221-408C-BCE1-E43B889D2E30Q41518498-E3B7D43D-5018-4C42-91C6-213068D59C49
P2860
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@ast
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@en
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@nl
type
label
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@ast
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@en
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@nl
prefLabel
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@ast
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@en
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@nl
P1433
P1476
IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
@en
P2093
Froogh Darakhshan
Stephane Perrier
P304
P356
10.1016/J.FEBSLET.2006.10.061
P407
P50
P577
2006-11-03T00:00:00Z